SCHEMBL838153

SCHEMBL838153

Cc1ccc(C)c(-n2ncc3c(O)ncnc32)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.55
HPGD P15428 5/20 0.52
HTT P42858 4/20 0.52
ALDH1A1 P00352 4/20 0.52
LMNA P02545 6/20 0.51
KDM4E B2RXH2 4/20 0.51
PIP4K2A P48426 2/20 0.51
NPC1 O15118 1/20 0.51
PKM P14618 1/20 0.51
TP53 P04637 5/20 0.49
MAPT P10636 4/20 0.48
ALOX15 P16050 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
GAA P10253 1/20 0.46
NTSR1 P30989 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839998 0.86 TP53 (0.47) RAB9AHTTLMNAKDM4EPIP4K2A
SCHEMBL12414262 0.84 RAB9A (0.53) RAB9AHPGDHTTALDH1A1LMNA
SCHEMBL839601 0.83 RAB9A (0.55) RAB9AHPGDHTTALDH1A1LMNA
SCHEMBL839756 0.83 XDH (0.46) RAB9ALMNATP53MAPT
SCHEMBL850157 0.83 TP53 (0.45) RAB9AHTTLMNAKDM4EPIP4K2A
SCHEMBL839746 0.81 GSK3B (0.45) RAB9AHPGDHTTALDH1A1LMNA
SCHEMBL838986 0.76 RAB9A (0.41) RAB9AHPGDHTTALDH1A1LMNA
SCHEMBL838405 0.73 TP53 (0.44) RAB9AHTTALDH1A1LMNAKDM4E
SCHEMBL838447 0.73 RAB9A (0.40) RAB9AHPGDHTTALDH1A1LMNA
SCHEMBL6263777 0.72 RAB9A (0.70) RAB9AHPGDHTTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
EP-2324028-A2 THERAPEUTIC AGENTS 414 AstraZeneca AB (SE) 2011-05-25 EP disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 RAB9A 3239/4885HPGD 694/4885HTT 2010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.